Scholar Rock gets first FDA nod for rare muscle-wasting disease

The FDA has granted its first approval to Scholar Rock for a rare muscle-wasting disease treatment, marking a significant regulatory milestone in rare disease therapeutics.

This Wire brief sits within Fusion42's coverage of Biotech.